Promising Dual Immunotherapy for Anaplastic Thyroid Cancer

By Rene Pretorius

January 10, 2025

We review the results from the phase 2 nonrandomized clinical trial on the clinical activity of dual immune checkpoint inhibition in aggressive thyroid cancer. The purpose of the study was to evaluate the efficacy of anti-programmed cell death 1 nivolumab and anti-cytotoxic lymphocyte-associated protein 4 ipilimumab in patients with aggressive thyroid carcinoma. The study presents significant findings on the promising role of dual immunotherapy in treating anaplastic thyroid cancer (ATC) and other aggressive thyroid cancers.

Dual Immunotherapy

The article discusses a phase 2 trial (NCT03246958) that evaluated the efficacy of dual immune checkpoint inhibition using nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with aggressive thyroid cancers. This approach focuses on enhancing the immune system’s ability to target cancer cells effectively.

Efficacy in ATC

For patients with anaplastic thyroid cancer (ATC), the trial showed a promising response. Out of 10 patients with ATC, there was a notable 30% objective response rate (ORR; 95% CI, 6.7%-65.2%), and 50% of the patients demonstrated a clinical benefit. These results highlight the potential of dual immunotherapy in improving outcomes for those affected by this aggressive cancer subtype.

Comparison with Other Thyroid Cancers

In contrast, the same dual immunotherapy regimen showed limited benefit for patients with radioiodine refractory differentiated thyroid carcinoma (RAIR DTC). Only 9.4% of the 32 patients with RAIR DTC had an objective response, all of which were partial responses, indicating a need for different therapeutic strategies.

Medullary Thyroid Carcinoma (MTC)

Among the exploratory cohort of patients with medullary thyroid carcinoma (MTC), researchers reported no responses to the treatments. These results underscore the variability in the response to dual immunotherapy across different thyroid cancer types.

Biomarker Analysis

The analysis linked the presence of NRAS tumor genetic sequence variations to worse outcomes in terms of response to therapy. However, the study found that BRAF V600E mutations did not influence the treatment response, highlighting the complexity of biomarker roles in treatment efficacy.

Implications

The study suggests dual immunotherapy with nivolumab and ipilimumab may benefit some ATC patients. The trial’s small sample size limits conclusions. Further research is needed due to limited ATC treatment options.

Different thyroid cancer types show varying responses, requiring personalized strategies based on cancer subtype and genetic profile. These factors significantly influence outcomes.

Overall, immunotherapy, especially dual immunotherapy, shows promise for anaplastic thyroid cancer, which is hard to treat traditionally.

The evolving landscape of treatment strategies underscores the importance of targeted approaches in managing aggressive forms of cancer. Additional coverage can be read here.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.